Reproductive & Hormonal
Triptorelin
Trelstar; triptorelin pamoate
1 min read · Updated July 27, 2026 · 3 references
Curated by PeptideInfo Wikilast reviewed how we verify
An approved long-acting GnRH agonist depot used in the United States for palliative treatment of advanced prostate cancer.
Evidence: Regulator-approved drug with human trial evidence.
Approved in: FDA (United States; Trelstar for advanced prostate cancer)
- An approved long-acting GnRH agonist depot used in the United States for palliative treatment of advanced prostate cancer.
- Initial receptor stimulation is followed by pituitary GnRH-receptor desensitization and suppression of LH, FSH and gonadal sex hormones.
- Treatment can cause an initial tumor flare, hot flushes, metabolic and cardiovascular effects, QT prolongation and loss of bone density; the label requires clinical monitoring.
An approved long-acting GnRH agonist depot used in the United States for palliative treatment of advanced prostate cancer.
Overview
An approved long-acting GnRH agonist depot used in the United States for palliative treatment of advanced prostate cancer.
Primary regulatory source
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.
Identity and mechanism
Initial receptor stimulation is followed by pituitary GnRH-receptor desensitization and suppression of LH, FSH and gonadal sex hormones.
PubChem CID 25074470; C64H82N18O13; 1311.4 Da.
Regulatory label facts
FDA (United States; Trelstar for advanced prostate cancer).
The dose below reproduces a regulator-approved label; it is not a treatment recommendation. Trelstar intramuscular depot: 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks.
Safety boundary
Treatment can cause an initial tumor flare, hot flushes, metabolic and cardiovascular effects, QT prolongation and loss of bone density; the label requires clinical monitoring.
This is an educational reference, not individual medical advice. Use requires a prescriber and indication-specific monitoring.
References
Frequently asked questions
- What is Triptorelin?
- An approved long-acting GnRH agonist depot used in the United States for palliative treatment of advanced prostate cancer.
- Is Triptorelin approved as a medicine, and where?
- It is an approved prescription medicine, but where it is approved matters: FDA (United States; Trelstar for advanced prostate cancer). It should only be used under medical supervision.
- What is Triptorelin studied for?
- Triptorelin is most often discussed in the context of approved peptide medicines — verification pilot. Being studied for an area does not mean it is proven or approved for it.
- Does Triptorelin have human clinical trials?
- Yes. Triptorelin has been studied in human clinical trials and is an approved medicine in at least some regions.
Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. Triptorelin is an approved medicine within the stated approval scope (FDA (United States; Trelstar for advanced prostate cancer)) and must only be used under medical supervision; research-grade or unprescribed material is not a lawful substitute. Consult a qualified healthcare professional before making health decisions.